Andere talen Immuneering Corporation

Aandelen

IMRX

US45254E1073

Beurs gesloten - Nasdaq Andere beurzen 22:30:01 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,64 ^USD	+5,13%		+11,56%	-77,69%

09/04	Immuneering Corporation presenteert preklinische gegevens op de jaarlijkse bijeenkomst van de American Association for Cancer Research	CI
02/04	IMMUNEERING CORPORATION : Mizuho Securities herhaalt koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models	09/04
Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting	09/04
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference	03/04
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations	27/03
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations	27/03
Immuneering Announces First Patient Dosed in Its Phase 1/2A Trial of Imm-6-415 to Treat Advanced Solid Tumors with Raf or Ras Mutations	27/03
March Madness Market Movers: INBS, NCMI, CIFR, IMRX, STI	20/03
North American Morning Briefing : Investors -2-	18/03
Sector Update: Health Care Stocks Ease Late Afternoon	15/03
Sector Update: Health Care	15/03
Immuneering Shares Decline After Analysts Downgrades, Phase 1 Cancer Therapy Data	15/03
North American Morning Briefing : Inflation -2-	15/03
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors	14/03
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors	14/03
Immuneering Announces Positive Topline Results from Phase 1 Portion of Its Phase 1/2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors	14/03
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors	12/03
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors	12/03
Immuneering Corporation Appoints Thomas J. Schall to Its Board of Directors	12/03
Immuneering Begins Phase 2a Testing of Potential Cancer Immunotherapy; Phase 1 Data Due Out Soon	11/03
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors	11/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Immuneering Corporation

Aandelen

IMRX

US45254E1073

Andere talen

Filters